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Introduction: Staphylococcus aureus bacteremia (SAB) is the second-most common cause of 
community-onset (CO) bacteremia. The incidence of methicillin-resistant S. aureus (MRSA) has 
recently decreased across much of the United States, and we seek to describe risk factors for CO-
MRSA bacteremia, which will aid emergency providers in their choice of empiric antibiotics.
Methods: This is a retrospective cohort study of all patients with SAB at a 500-bed safety net hospital. 
The proportion of S. aureus isolates that were MRSA ranged from 32-35% during the study period. 
Variables of interest included age, comorbid medical conditions, microbiology results, antibiotic 
administration, duration of bacteremia, duration of hospital admission, suspected source of SAB, 
and Elixhauser comorbidity score. The primary outcome was to determine risk factors for CO-MRSA 
bacteremia as compared to methicillin-susceptible S. aureus (MSSA) bacteremia in patients admitted 
to the hospital through the emergency department.
Results: We identified 135 consecutive patients with CO-SAB. In comparison to those with MSSA 
bacteremia, patients with MRSA bacteremia were younger (odds ratio [OR] 0.5, 95% confidence 
interval [CI], 0.4-0.7) with higher Elixhauser comorbidity scores (OR 1.4, 95% CI, 1.1-1.7). Additionally, 
these patients were more likely to have a history of MRSA infection or colonization (OR 8.9, 95% CI, 
2.7-29.7) and intravenous drug use (OR 2.4, 95% CI, 1.0-5.7).
Conclusion: SAB continues to be prevalent in our urban community with CO-MRSA accounting for 
almost one-third of SAB cases. Previous MRSA colonization was the strongest risk factor for current 
MRSA infection in this cohort of patients with CO-SAB. [West J Emerg Med. 2019;20(3)438–442.]
INTRODUCTION
Staphylococcus aureus bacteremia (SAB) is the second-
most common cause of community-onset (CO) bacteremia, 
affecting 15-40 per 100,000 population per year.1,2 It is 
associated with a 20% mortality rate3,4 with higher mortality 
linked to the presence of methicillin resistance, comorbid 
conditions, intensive care unit admission, and prior exposure 
to antibiotics.5 Three-quarters of SAB are CO bacteremia, with 
the majority being secondary to skin and soft tissue infections. 
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While the incidence of hospital-acquired SAB is decreasing, 
the incidence of CO-SAB has remained stable.6 
The epidemiology of methicillin-resistant S. aureus 
(MRSA) has changed over the past four decades. Initially, 
MRSA was identified as a healthcare-associated pathogen.7 
In the late 1980s, community-onset MRSA, primarily the 
USA300 strain, was first identified. It spread throughout 
healthy community members including children, athletes, 
military personnel, and inmates in the 1990s.8,9 By the mid-
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2000s, the USA300 strain became the predominant strain of 
MRSA in both CO and healthcare-associated cases.10 In fact, 
MRSA accounted for approximately 50% of all S. aureus 
cases at its peak. Most recently, MRSA has been decreasing in 
comparison to methicillin-susceptible S. aureus (MSSA).6 
Risk factors for CO-MRSA have been poorly described in 
the recent era of decreasing MRSA prevalence. An evaluation of 
current risk factors for CO-MRSA is important for emergency 
medicine (EM) providers because it can impact the choice 
of empiric antibiotic therapy and prompt the early initiation 
of infection control measures. The goal of this study was to 
describe risk factors for CO-MRSA in a cohort of outpatients 
presenting to the emergency department (ED) with CO-SAB. 
METHODS
This is a retrospective cohort study of all patients with 
SAB at a 500-bed safety net hospital. The proportion of S. 
aureus isolates that were MRSA ranged from 32-35% during 
the study period. Patients were identified by review of the 
microbiology blood culture log. We included consecutive 
patients ≥ 18 years old with SAB occurring before hospital 
day three between June 1, 2013, and April 30, 2015, admitted 
through the ED. Pediatric patients, those with subsequent 
episodes of SAB during the study period, and those with 
incomplete microbiology data were excluded. Clinical and 
microbiological data were collected by manual review of the 
electronic medical record.
The primary outcome was to determine risk factors for 
CO-MRSA bacteremia, as compared to MSSA bacteremia. 
Variables of interest were predetermined before the study 
began and included age, comorbid medical conditions, 
presence of indwelling medical devices including orthopedic 
hardware and intravascular devices (i.e., pacemakers, 
prosthetic heart valves, arterial grafts, and patches), 
microbiology results, antibiotic administration, duration of 
bacteremia, duration of hospital admission, suspected source 
of SAB, and Elixhauser comorbidity score.11 The Elixhauser 
comorbidity score is a collection of 30 variables that are 
predictive of inhospital mortality. 
The infectious diseases service performs a consultation 
on all patients with SAB. The suspected source of SAB was 
determined by an infectious diseases specialist (Heather L. 
Young) reviewing the infectious diseases consultation notes 
and using the following guidance to define the source of SAB: 
•	 Skin and soft tissue infection: cellulitis or purulence in the 
superficial skin layers without a deeper underlying source 
and without a history of injection drug use (IDU).
•	 Vascular access: (1) pain, erythema, or phlebitis at a 
recent or current peripheral intravenous (IV) catheter, at 
a recent phlebotomy site, or overlying an arteriovenous 
fistula; or (2) a central venous catheter, including 
hemodialysis catheter, with pain, erythema, or purulence 
at the insertion site or without those symptoms but with 
no other recognized source of infection.12 
•	 Bone or joint infection: purulence or a positive culture for 
S. aureus isolated from bone or synovial fluid. 
•	 IDU: skin and soft tissue infection at a site used for 
injecting drugs.
•	 Pneumonia: pulmonary infiltrates accompanied by hypoxia.
•	 Urinary tract infection: a urine culture positive for S. 
aureus plus dysuria, urinary frequency, or radiologic 
evidence of pyelonephritis. 
•	 Other: radiologic evidence of infection plus a tissue 
culture positive for S. aureus in a body site. 
•	 Unknown: does not fit the definition of other sites of infection.
We used descriptive statistics to characterize the population. 
Chi-square, Wilcoxon rank-sum, and multivariate logistic 
regression were used to determine the relationship between the 
primary outcome and the variables of interest. Factors with a 
univariate p-value < 0.3 were considered for the multivariate 
model. We performed all statistics using Statistical Analysis 
System version 9.0 (Cary, North Carolina). This study was 
approved by the Colorado Multiple Institutions  Institutional 
Review Board. 
RESULTS
During the study period, we identified 178 patients with 
SAB of whom 43 were excluded: 39 (22%) had a hospital-
onset infection; three patients had a second case of SAB during 
the study period; and one SAB was not speciated. Thus, 135 
patients with CO-SAB were included. The median patient age 
was 55.7 years (interquartile range [IQR] 48.9-63.6), and 77% 
(n=105) were male. The most common comorbid conditions 
included diabetes mellitus (n=68, 50%), chronic kidney disease 
(n=28, 20%), IDU (n=27, 20%), cirrhosis (n=27, 20%), and 
malignancy (n=15, 11%). Twenty patients (15%) had a history 
of MRSA infection or colonization. The median Elixhauser 
score was 4.0 (IQR 3.0-5.0). 
Skin and soft tissue infections were responsible for the 
largest proportion of SAB cases (n=65, 48%), followed by 
unknown source (n=38, 28%) and vascular catheters (n=19, 
14%). MRSA bacteremia accounted for 32% (n=43) of CO-
SAB cases. In comparison to those with MSSA bacteremia, 
patients with MRSA bacteremia were younger (odds ratio 
[OR] 0.5 for 10-year increments, 95% confidence interval 
[CI], 0.4-0.7) with higher Elixhauser comorbidity scores (OR 
1.4 for one-unit increments; 95% CI, 1.1-1.7). Additionally, 
these patients were more likely to have a history of MRSA 
infection or colonization (OR 8.9; 95% CI, 2.7-29.7) and IDU 
(OR 2.4; 95% CI, 1.0-5.7) (Table). 
DISCUSSION
In this cohort of patients with CO-SAB, we found that 
patients with CO-MRSA bacteremia were younger, more likely 
to have previous MRSA colonization or infection, and more 
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Population Univariate Multivariate
Variable
MSSA
N = 92
MRSA
N = 43 OR 95% CI OR 95% CI P value
Age, median years (IQR) 58 (52-65) 52 (43-57) 0.95 0.92-0.98 0.5 0.4-0.7 < 0.0001
Elixhauser score, median (IQR) 4 (3-5) 5 (3-6) 1.18 0.98-1.41 1.4 1.1-1.7 0.01
Diabetes mellitus, n (%) 47 (51) 19 (44) 0.76 0.37-1.60
 Hemoglobin A1C, median (IQR) 9 (7-10) 9 (7-12) 1.11 0.90-1.37
Chronic kidney disease, n (%) 21 (23) 7 (16) 0.65 0.25-1.67
Hemodialysis, n (%) 9 (10) 3 (7) 1.45 0.37-5.63
End-stage liver disease 18 (20) 7 (16) 0.79 0.30-2.06 0.4 0.1-1.3 0.13
Rheumatologic disease, n (%) 1 (1) 1 (2) 2.14 0.13-35.09
Malignancy, n (%) 11 (12) 5 (12) 0.96 0.31-2.95
Injection drug use, n (%) 14 (15) 13 (30) 2.38 1.00-5.66
Human immunodeficiency virus, n (%) 1 (1) 2 (5) 4.39 0.39-49.80
Intravascular device, n (%) 10 (11) 0 (0)
History of MRSA infection or colonization, n (%) 5 (5) 14 (33) 8.4 2.78-25.34 8.9 2.7-29.7 < 0.0001
History of S. aureus bacteremia 5 (5) 1 (2) 0.41 0.05-3.66
Presence of orthopedic hardware 6 (7) 5 (12) 1.89 0.54-6.56 3.2 0.8-12.8 0.10
Presumed source of infection
Skin and soft tissue infection 28 (30) 15 (34) 1.22 0.57-2.64
Vascular access 13 (14) 6 (14) 0.99 0.35-2.80
Bone or joint infection 8 (9) 6 (14) 1.38 0.42-4.50
Injection drug use 6 (6) 5 (11) 1.89 0.54-6.56
Pneumonia 5 (5) 2 (5) 0.85 0.16-4.56
Urinary tract infection 4 (4) 3 (7) 1.65 0.35-7.72
Other 4 (4) 2 (5) 1.07 0.19-6.10
Unknown source 25 (27) 5 (11) 0.37 0.13-1.06
Table. Demographic information plus univariate and multivariate odds ratios of risk factors for patients with community-onset methicillin-
resistant and methicillin-susceptible S. aureus bacteremia.
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; IQR, interquartile range; OR, odds ratio; 
CI, confidence interval. 
likely to have comorbid medical conditions than those with 
CO-MSSA bacteremia. We were surprised to see that both 
younger patients and those with comorbid conditions were at 
risk for CO-MRSA bacteremia. We suspect that this is due to 
an interaction between age and IDU (p = 0.003 on univariate 
analysis). Younger age was a previously described risk factor 
for CO-MRSA due to the USA300 strain, while increased 
comorbid conditions is a traditional risk factor for CO-MRSA. 
It would be interesting to determine if there is one predominant 
strain of MRSA in CO-MRSA at the current time, or if there are 
different strains prevalent in these two demographic groups. 
Previous MRSA colonization or infection was the 
strongest risk factor for CO-SAB due to MRSA in our study. 
Our results are concordant with the work of Butler-Laporte 
et al.13 who found that the presence of a positive MRSA 
nares screen at any time in the past was associated with a 
high risk of MRSA infection in the context of a presumed 
SAB. Similarly, Bradley et al.14 reported that 12% of patients 
who newly acquire MRSA are hospitalized with an MRSA 
infection in the subsequent 18 months. Our study also 
correlates with the results of Yasmin et al.4 who reported that 
the majority of CO-MRSA bacteremia cases were due to skin 
and soft tissue infections. Yasmin et al.4 also found that having 
a central line within the previous 30 days was an independent 
risk factor with a calculated OR of 80 (95% CI, 2-3014). 
In our study, episodes of vascular access, including central 
line, dialysis catheters, peripheral IV, and venipuncture, were 
common sources of CO-SAB. 
The changing epidemiology of MRSA is of interest to 
emergency care providers. As the first providers to evaluate 
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patients with community-onset infections, emergency 
physicians are responsible for initiating appropriate antibiotic 
therapy both for resistant and susceptible pathogens. There 
are certainly risks to providing an insufficient spectrum of 
antibiotics to patients in the setting of sepsis. Patients who 
do not receive an appropriate antibiotic within the first three 
hours of presenting to the ED have increased mortality as 
compared to those who receive antibiotics that are active 
against the causative pathogen.15 
However, there are also risks associated with administering 
antibiotics that are too broad in spectrum, including placing 
patients at higher risk for Clostridioides difficile colitis, 
encouraging the emergence of multidrug resistant organisms, 
and suboptimally treating severe infections. While most 
antibiotics incur some risk for C. difficile colitis, broad spectrum 
antibiotics such as clindamycin, third-generation cephalosporins, 
and fluoroquinolones place a patient at the highest risk for this 
infection.16 Additionally, the widespread use of an antibiotic can 
drive resistance in this organism within a hospital community. 
For example, Kim et al.17 described a relationship between 
increasing numbers of vancomycin doses administered at their 
hospital and an increasing number of patients with vancomycin-
resistant enterococcus infection. Finally, broad spectrum therapy 
is not always the most effective antibiotic for a particular 
pathogen. Vancomycin is the most common empiric treatment 
of suspected MRSA bacteremia, but vancomycin is associated 
with inferior outcomes for MSSA bacteremia as compared to 
cefazolin or nafcillin therapy.18 By understanding risk factors 
for both MRSA and for MSSA, emergency physicians may be 
able to select antibiotics in a more nuanced fashion, choosing 
not only an adequate drug for S. aureus infection, but also the 
most effective therapy for either MRSA or MSSA based on the 
patient’s risk factors for the organism. 
Emergency care providers also have the opportunity to 
promptly initiate appropriate infection control measures. If a 
patient has risk factors for MRSA, contact precautions may be 
implemented while the patient is still in the ED, appropriate 
environmental cleaning processes may be started, and a 
private inpatient room can be requested to decrease the risk of 
transmission to other vulnerable patients. 
LIMITATIONS
This study is limited by its single-center design. Results 
may not be applicable to facilities that care for a large 
population of outpatients with indwelling central lines or 
whose communities have different rates of MRSA. Further 
studies to characterize the strains of MRSA causing these 
infections would be an interesting correlate. 
CONCLUSION
CO-SAB continues to be prevalent in our urban 
community, with CO-MRSA accounting for almost one-
third of SAB cases. Previous MRSA colonization was the 
strongest risk factor for current MRSA infection in this cohort 
of patients with CO-SAB. The demographics of adults with 
CO-MRSA bacteremia continue to evolve, currently being a 
hybrid between chronically-ill patients and those with young 
age. Emergency physicians must be aware of the changing 
risk factors for MRSA so that optimal antibiotic therapy and 
infection control measures can be initiated in a timely manner. 
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